Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 24, 2019

Primary Completion Date

April 10, 2020

Study Completion Date

April 10, 2020

Conditions
Alopecia Areata
Interventions
DRUG

CTP-543

Administered as 12 mg tablets.

DRUG

CTP-543 Matching Placebo

Administered as tablets to aid treatment masking.

Trial Locations (12)

33613

ForCare Clinical Research, Tampa

46168

The Indiana Clinical Trials Center, PC, Plainfield

78660

Austin Institute for Clinical Research, Inc., Pflugerville

80111

Colorado Center for Dermatology and Skin Surgery, Centennial

02114

Massachusetts General Hospital, Boston

L4M 7G1

SimcoDerm Medical and Surgical Dermatology Center, Barrie

N1L 0B7

Guelph Dermatology Research, Guelph

N6H 5L5

Dr Wei Jing Loo Medicine Professional Corporation, London

L3P 1X2

Lynderm Research Inc., Markham

L6J 7W5

The Centre for Clinical Trials, Oakville

M4W 2N4

Research Toronto, Toronto

H2X 2V1

Innovaderm Research Inc., Montreal

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY